6533b86dfe1ef96bd12c9553
RESEARCH PRODUCT
Survival of European patients diagnosed with lymphoid neoplasms in 2000-2002: results of the HAEMACARE project.
Rafael Marcos-grageraC AllemaniC TereanuR De AngelisR CapocacciaM MaynadieS LuminariS FerrettiTb JohannesenR Sankila KarjalainenMl LindsbergA SimonettiMc MartosM RaphaëlP GiraldoM Sant Haemacare Working GroupMarina Vercellisubject
MaleLimfomesLymphomaDiseaseLymphoid neolasmas survival0302 clinical medicineEpidemiology80 and overRegistriesChildAged 80 and overLeukemialymphoid neoplasmsIncidenceRegistries/statistics & numerical dataAge FactorsHematologyMiddle Aged3. Good healthEuropeSurvival RateChild Preschool030220 oncology & carcinogenesisFemaleLymphomasLymphoid neolasmas survival; Europe.Adultmedicine.medical_specialtyAdult; Age Factors; Aged; Aged 80 and over; Child; Child Preschool; Europe; Female; Humans; Incidence; Infant; Infant Newborn; Leukemia; Lymphoma; Male; Middle Aged; Registries; Sex Factors; Survival Analysis; Survival Rate; Young AdultNOEurope/epidemiology03 medical and health sciencesYoung AdultSex FactorsInternal medicinemedicineHumansLeukemia/classification/epidemiology/mortalityCancer survival; lymphoid neoplasmsPreschoolSurvival rateSurvival analysisddc:613AgedTumorsbusiness.industryPublic healthInfant NewbornCancerInfantLymphoma/classification/epidemiology/mortalityOriginal Articlesmedicine.diseaseNewbornSurvival AnalysisCancer survivalSurgeryCancer registrybusinessInternational Classification of Diseases for Oncology030215 immunologydescription
The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set up to improve the availability and standardization of data on hematologic malignancies in Europe, used the European Cancer Registry-based project on survival and care of cancer patients (EUROCARE-4) database to produce a new grouping of hematologic neoplasma(defined by the International Classification of Diseases for Oncology, Third Edition and the 2001/2008 World Health Organization classifications) for epidemiological and public health purposes. We analyzed survival for lymphoid neoplasms in Europe by disease group, comparing survival between different European regions by age and sex. Design and Methods Incident neoplasms recorded between 1995 to 2002 in 48 population-based cancer registries in 20 countries participating in EUROCARE-4 were analyzed. The period approach was used to estimate 5-year relative survival rates for patients diagnosed in 2000-2002, who did not have 5 years of follow up. Results: The 5-year relative survival rate was 57% overall but varied markedly between the defined groups. Variation in survival within the groups was relatively limited across European regions and less than in previous years. Survival differences between men and women were small. The relative survival for patients with all lymphoid neoplasms decreased substantially after the age of 50. The proportion of ‘not otherwise specified’ diagnoses increased with advancing age.Conclusions: This is the first study to analyze survival of patients with lymphoid neoplasms, divided into groups characterized by similar epidemiological and clinical characteristics, providing a benchmark for more detailed analyses. This Europe-wide study suggests that previously noted differences in survival between regions have tended to decrease. The survival of patients with all neoplasms decreased markedly with age, while the proportion of ‘not otherwise specified’ diagnoses increased with advancing age. Thus the quality of diagnostic work-up and care decreased with age, suggesting that older patients may not be receiving optimal treatment
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-02-17 |